The prominent role of CERAMENTTIG at this year’s EBJIS demonstrates BONESUPPORT’s commitment to advancing the scientific understanding of osteomyelitis,” said Lloyd Diamond, CEO of BONESUPPORTT.  “Our research and development efforts are focused on multiple pathways for our unique platform technology which we believe may lead to new treatment options for patients.”

“EBJIS is an important scientific meeting to expand and share knowledge of bone and joint infections, which affects 150 million people worldwide each year,” said Martin McNally, Lead Surgeon of the Bone Infection Unit at the Nuffield Orthopaedic Centre in Oxford, UK and President-Elect of EBJIS.  “CERAMENTTIG offers an exciting advancement in the management of osteomyelitis, compared to previous antibiotic delivery systems and I am pleased to share the favorable results that we have seen in our study.”

Key data presented represent findings from benchmark testing, pre-clinical and clinical studies in a wide range of indications and representing several key centers throughout Europe and the United States.

·         A comparative study of three bioabsorbable antibiotic carriers in chronic osteomyelitis:  313 patients with minimum 1 year follow-up.  M. McNally, et al – Oxford University Hospitals, Oxford, United Kingdom.  Results:  50% less fractures and infection recurrence with CERAMENTT’G as compared to other two products.

·         CERAMENTT’BONE VOID FILLER with gentamicin increases bone formation and decreases detectable infection in a rat model of debrided osteomyelitis.  A. Dvorzhinskiy, M. Bostrom, et al – Hospital for Special Surgery, New York, United States.  Results:  Significant decrease in infection, increase in bone growth and no infection recurrence at 6 months with CERAMENTT’G.

·         Use of a new antibiotic bone substitute to induce healing of osteomyelitis in the diabetic foot.  C. Whisstock, et al – Diabetic Foot Clinic, Foot and Ankle Clinic, Abano Terme, Italy.  Results:  Rapid resolution of osteomyelitis with rapid tissue closure and preservation of diabetic feet with CERAMENTT’G.

·         In-vivo gentamicin concentrations in plasma and drain fluid after bone defect reconstruction using a gentamicin-eluting bone graft substitute.  P. Horstmann, W. Hettwer, et al – University of Copenhagen.  Results:  The high local peak concentration of gentamicin found in this study would be expected to deliver a substantial prophylactic effect after long operations with an increased risk of intraoperative bacterial contamination.

·         An injectable bone substitute eluting antibiotic in the treatment of traumatic bone defects and its prophylactic effect.  D. Papadia, et al – Trento, Italy.  Results:  No infections in 15 patients treated prophylactically following open fractures with a mean follow up of 11 months.  Rapid bone formation noted at 6 months.

·         CERAMENTT with gentamicin regenerates bone in osteomyelitis with muscle acting as an osteoinductive niche. Raina, W. Hettwer, M. McNally, L. Lidgren, et al – Lund University Hospital, Lund, Sweden.  Results:  Clinical observations with rapid bone formed in CERAMENTT’G and in some cases in the muscle indicate osteoinductive potential.

·         The efficacy of injectable biphasic calcium sulphate/hydroxyapatite bone substitute CERAMENTT’G in the treatment of severe bone infections.  C. Pempinello, et al – S. Gennaro Hospital, Napoli, Italy.  Results:  Three septic non-union cases treated with CERAMENTT’G with 8-18 months follow-up.  There were no recurrences of infection and bone growth occurred in all cases.

·         Antibiotic loaded resorbable bone-graft substitute:  A new treatment for osteomyelitis in diabetic foot syndrome.  B. Gächter, et al – Locarno and Lugano, Switzerland.  Results:  A one-step surgical approach with CERAMENTT’G allowed for a minimal meta tarsal head resection while foot structure was maintained in the diabetic patient.

·         Analysis of drain fluid particle content after implantation of an antibiotic-eluting bone graft substitute close to a partial pelvic replacement.  W. Hettwer, et al -Denmark and Sweden.  Results:  SEM imaging demonstrated that no potentially wear inducing HA particles originating from CERAMENTT’G were observed in the drain fluid of patients in this pilot study.

·         Use of a gentamicin eluting bone graft substitute in the treatment of peri-prosthetic joint infection in a tumor shoulder replacement.  C. Jensen, W. Hettwer, et al – Rigshospitalet, Copenhagen, Denmark.  Results:  CERAMENTT’G used in a second stage re-implantation of an infected proximal humeral replacement.  At 18 months post-op, the patient’s shoulder remains pain free and stable without signs of persistent or reinfection.

·         Staged ankle fusion using a hindfoot nail and CERAMENTT’G in cases of ankle osteomyelitis after open pilon fractures.  P. Corona, et al – Vall d’Hebron University Hospital, Barcelona, Spain.  Results: CERAMENTT’G used in a series of challenging foot and ankle cases with compromised soft tissue.  Fusion was achieved at 4 months in all cases.


BONESUPPORTT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G and CERAMENTT’V are not available in the United States.

CERAMENTT is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENTT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENTT spans more than eleven years. Over fifty pre-clinical, clinical and animal studies have been conducted and more than 20,000 patients have been treated with CERAMENTT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORTT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Phone +46 46 286 53 60


Lundbeckfonden øger sit engagement i IO Biotech
12. januar 2021
Lundbeckfonden lancerer 2030-strategi med ambitiøse mål for både uddelings- og erhvervsaktiviteterne
22. december 2020
Lundbeckfonden uddeler 57 mio. kr. til dristige projekter
15. december 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge